KRAS and cancer: Although therapeutic strategies such as small molecule inhibitors (targets upstream & downstream effectors, direct KRAS and its regulators, cell cycle regulators); siRNA candidates; cancer vaccines; PROteolysis TArgeting Chimers (PROTACs); Antibody–Drug conjugates (ADCs); and Immunotherapies are being developed [9, 12].